Search results
Showing 1 to 5 of 5 results for tafamidis
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)
Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.
Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]
In development [GID-TA11598] Expected publication date: 12 November 2025
Systemic lupus erythematosus (active) - belimumab 18 July 2012 TA696 Tafamidis for treating transthyretin amyloid cardiomyopathy 4-5...
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)
This guidance has been updated and replaced by NICE technology appraisal guidance 984.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.